ArticleDermatology and therapy2026
Real-World Long-Term Effectiveness and Safety of Secukinumab in Psoriasis: Up to 7 Years of Evidence from the Italian Landscape Psoriasis (IL PSO) Multicenter Retrospective Study.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSecukinumab, approved in 2015 for the treatment of moderate-to-severe psoriasis, has demonstrated sustained efficacy and safety in pivotal randomized controlled trials. However, real-world data on its long-term effectiveness and safety are limited. We conducted a multicenter retrospective study involving 15 Italian dermatology units to assess the long-term effectiveness and safety of secukinumab in routine clinical practice over a period of up to 7 years.
methodsA total of 769 adult patients with moderate-to-severe psoriasis who received continuous secukinumab treatment for at least 4 years were included. We assessed effectiveness in terms of the Psoriasis Area and Severity Index (PASI) 90 and 100 (complete skin clearance) and an absolute PASI score of ≤ 2 at various time points from week 16 to 7 years. We performed subgroup analyses to evaluate the impact of different comorbidities. Safety was assessed by recording all adverse events (AEs) reported during follow-up visits.
resultsPASI 90 was achieved by 36.0% of patients at week 16, increasing to 71.0% at year 1, 84.1% at year 4, 87.0% at year 5, and 90.0% at year 6. PASI 100 rates rose from 27.4% at week 16 to 67.1% at year 4 and 80.2% at year 7. Patients with concomitant psoriatic arthritis (PsA) showed significantly higher PASI 100 rates at years 5 and 6 (p ≤ 0.05). The overall incidence of AEs was low, with serious AEs occurring in a small number of patients. Treatment was permanently discontinued due to adverse drug reactions in five patients (three due to de novo malignancies, one due to eosinophilic pneumonia, and one due to massive pulmonary embolism).
conclusionsIn this selected cohort of long-term responders, secukinumab demonstrated sustained and progressively increasing effectiveness with a favorable safety profile over up to 7 years of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.